Royalty Report: Drugs, Cancer, Drug Discovery – Collection: 371879

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Drugs
  • Cancer
  • Drug Discovery
  • Disease
  • Therapeutic
  • Pharmaceuticals
  • Delivery
  • Central Nervous System
  • Biotechnology
  • Drug delivery
  • Stem cells
  • Nanoparticles
  • Diagnostic
  • Ophthalmological
  • Pain
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 371879

License Grant
Licensor in-licensed to Licensee the exclusive worldwide rights to the central nervous system (“CNS”) and/or cerebrocardiovascular drug application, including the (preventive) treatment of peripheral effects of agents causing CNS disease or symptoms, including cancer, for 2X-111.
License Property
2X-111 is an advanced, targeted liposomal formulation of Doxorubicin, one of the world’s most widely used chemotherapies. The specific 2X-111 formulation, which exploits a glutathione enhanced PEG-liposomal delivery system, may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.

Doxorubicin is a type of chemotherapy drug called an anthracycline. It slows or stops the growth of cancer cells by blocking an enzyme called topo isomerase 2, which is necessary for DNA replication. Topo isomerase 2 is an enzyme that cuts both strands of the DNA helix simultaneously in order to manage DNA tangles and supercoils.

Preclinical studies have been performed in order to determine the anti-cancer activity and toleration of 2X-111 both systemically and in the CNS prior to the start of the human clinical trials.

Field of Use
Field of use is for treatment of peripheral effects of agents causing CNS (central nervous system) disease or symptoms, including Cancer.

The right is  to the central nervous system (“CNS”) and/or cerebrocardiovascular drug application, including the (preventive) treatment of peripheral effects of agents causing CNS disease or symptoms, including cancer, for 2X-111

The central nervous system (CNS) is the part of the nervous system consisting primarily of the brain and spinal cord.

Cerebrovascular disease refers to a group of conditions, diseases, and disorders that affect the blood vessels and blood supply to the brain. If a blockage, malformation, or hemorrhage prevents the brain cells from getting enough oxygen, brain damage can result.

Licensee believes may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.

IPSCIO Record ID: 371877

License Grant
Licensor out-licensed our secondary LiPlaCis® and 2X-111 programs to Licensee of Norway for Phase 2 clinical development of each program together with its DRP® companion diagnostic. Licensor will support Licensee in these studies by providing DRP® companion diagnostic analysis for screened patients in each trial.
License Property
LiPlaCis® is an advanced, targeted liposomal formulation of Cisplatin, one of the world’s most widely used chemotherapies. The specific LiPlaCis® formulation utilizes a proprietary phospholipase A (sPLA2-IIA) cleavage substrate for controlled, selective hydrolyzation, disruption and release of drug payload in the presence of tumor cells. This delivery vehicle may result in drug accumulation directly at tumor site, thereby potentially increasing drug targeting at the tumor and reducing negative, off target drug effects and toxicity that is well known for cisplatin.

X-111 is an advanced, targeted liposomal formulation of Doxorubicin, one of the world’s most widely used chemotherapies. The specific 2X-111 formulation, which exploits a glutathione enhanced PEG-liposomal delivery system, it may allow 2X-111 to cross the blood-brain barrier (BBB), thereby potentially enabling the treatment of primary brain tumors, such as glioblastoma multiforme (GBM), and secondary brain tumors that originated from cancers outside the brain, such as metastatic breast cancer.

DRP® is a predictive biomarker platform to generate drug-specific companion diagnostics.  it is used as a companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by the DRP® companion diagnostics platform, that will potentially correlate with drug efficacy and patient response to treatment.

Field of Use
Field of use is for the treatment of metastatic breast cancer (mBC) and advance 2X-111 for the treatment of glioblastoma multiforme (GBM) such as brain tumors.

IPSCIO Record ID: 238361

License Grant
Licensor hereby grants to Licensee an exclusive license, even as to Licensor, under the Patent Rights, to research, develop, make, have made, use, offer to sell, sell, export and/or import and commercialize Licensed Products within the Licensed Territory for use within the Licensed Field. For purposes of clarity Licensee shall have the right, but not the obligation, to conduct research regarding the Patent Rights. For the avoidance of doubt and except as to the Patent Rights and rights to Technology granted, nothing in this Agreement shall serve to grant Licensee any right, title or interest to any other intellectual property right owned or controlled by Licensor. Moreover, Licensee agrees and acknowledges that nothing in this Agreement shall preclude Licensor from engaging in future research, development, production, distribution, sale or commercialization of any product or service in the Licensed Field, or which may compete with a Licensed Product, provided such product or service are not covered by the Patent Right licensed herein.
License Property
The technology and patents are for the chemical compound commonly known as Berubicin.  Berubicin is an anthracycline, which is a class of drugs that are among the most powerful chemotherapy drugs known and as a class are effective against more types of cancer than any other class of chemotherapeutic agents.

Berubicin is a novel therapy for the treatment of glioblastoma. Berubicin is one of the first anthracyclines (the most potent class of cancer drugs) to cross over the blood brain barrier and kill tumor cells in humans.

Glioblastoma is a type of astrocytoma, a cancer that forms from star-shaped cells in the brain called astrocytes. In adults, this cancer usually starts in the cerebrum, the largest part of your brain. Glioblastoma tumors make their own blood supply, which helps them grow

Field of Use
Licensed Field means the use of Licensed Product for the treatment of cancer through any type of administration, whether now known or yet to be developed.

IPSCIO Record ID: 351110

License Grant
Licensor licensed to Licensee patents and materials for the development and commercialization of novel cancer immunotherapy agent derived from the VAC platform utilizing an antigen provided by Licensee.
License Property
VAC platform is an allogeneic, or “off-the-shelf,” cancer immunotherapy derived from pluripotent stem cells for which a clinical trial in non-small cell lung cancer.
Field of Use
The collaboration will generate a novel product candidate derived from Licensor’s investigational allogeneic VAC cancer immunotherapy platform and targeting a proprietary Tumor Associated Antigen (TAA) construct provided by Licensee, for the treatment of glioblastoma multiforme (GBM).

Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive type of cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are nonspecific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke.

IPSCIO Record ID: 6343

License Grant
Initiated on March 22, 2006 as part of Cooperative Research and Development Agreement (CRADA), the Licensor has granted an exclusive, worldwide License to the Licensee.

The Licensor, government public health organization, desires to transfer certain inventions to the private sector through commercialization Licenses to facilitate the commercial development of products and processes for public use and benefit for the Treatment of Glioblastomas and other Central Nervous System (CNS) tumors.  Glioblastoma Multiforme is the most common and most aggressive type of primary human brain cancer. The name derives from the fact that the brain cell that loses growth control and becomes a brain cancer cell is a glial cell (glioblastoma); as the altered glial cells grow without restraint, they take on many different shapes (multiforme).

License Property
U.S. Provisional Patent Application No. 60/771,163, filed February 6, 2006, entitled Use of Phosphatases To Treat Glioblastomas (HHS Ref. No. E-123-2006/0-US-01);
    
U.S. Provisional Patent Application No. 60/797,201, filed May 2, 2006, entitled Use of Phosphatases To Treat Glioblastomas (HHS Ref. No. E-123-2006/1-US-01)          
  
U.S. Patent Application Serial No. 11/703,401, filed February 6, 2007, entitled Use of Phosphatases To Treat Glioblastomas (HHS Ref. No. E-123-2006/0-US-03)
Field of Use
Licensed Fields of Use Treatment of Glioblastomas and other Central Nervous System (CNS)tumors.

IPSCIO Record ID: 28043

License Grant
The University in England Licensor will assign to the Company of England the Intellectual Property in any of the Results including improvements, modifications, adaptations or developments for any purpose within the Field in the Territory.
License Property
The Scope of the Project is the identification of nanoparticles that effectively cross the blood brain barrier. The anticipated outputs or results are determination of which of the gold nanoparticles tested cross the human brain endothelium in the in vitro blood-brain barrier model, and whether they can target astrocytes.

The most effective nanoparticle carrier that targets astrocytes (neurological cells that continuously tile the entire central nervous system).

IPSCIO Record ID: 7111

License Grant
The Licensor, non-profit hospital, grants to Licensee the exclusive, worldwide License, with the right to grant subLicenses, to conduct research, develop Products, modify existing and/or future Products, and market such Products in the Field of Use using the Patent Rights and/or the Technical Information and to develop, use, make, have made, practice, import, carry out, manufacture, have manufactured, offer for sale, sell and/or have sold Products in the Field of Use in the territory using the Patent Rights and/or the Technical Information.
License Property
The Licensor owns and is entitled to grant License rights with respect to certain Patent Rights and Technical Information invented or developed in the course of the Licensor’s Molecular Oncology Research Program in the field of human therapeutic products, including new pharmaceutical products and/or non-prescriptive products based on, or utilizing the Patent Rights and/or Technical Information developed in the course of the Program.

Product or Products shall mean any human therapeutics, diagnostics (including algorithms or any components thereof), bioinformatics and any other human health care products and/or services in the Field of Use utilizing or derived in any manner whatsoever from any of the Patent Rights, Technical Information or Licensee Improvements, which Product(s), except for the license granted hereunder, would infringe a Valid Claim, the Patent Rights or those Future Patent Rights licensed to Licensee.

Licensee has developed a new anti-cancer agent as well as a new methodology specific for the treatment of invasive tumors such as glioblastoma multiforme, the most aggressive form of brain cancer, as well as both Her2-positive and Her2-negative breast cancers.

Licensee believes this approach is effective against brain and breast cancer in rodents, significantly extending their longevity and decrease the tumor size. Licensee proposes to expand this proprietary technology to other forms of cancer treatments together with common eye diseases such as age-related macular degeneration and diabetic retinopathy.

The technology is a family of related nano-biopolymers collectively referred to as Polycefin™ that are capable of acting as a drug delivery and targeting platform for cancer therapy and diagnostics. The new nanoscale drug, Polycefin, based on Licensee’s delivery system, was developed and patented by Licensee’s scientists. It is non-toxic, non-immunogenic, and biodegradable. It is based on a naturally derived polymer, i.e., polymalic acid. A significant feature of this novel agent is its ability to target multimeric tumor-associated proteins with one drug, a capability that other existing agents do not have. Licensee has proven that the significant anti-tumor and anti­angiogenic activity of this new drug is effective against both brain and breast cancers.

Polycefin are designed to target cancer cells and deliver a variety of bound therapeutics to them. In vivo pre-clinical studies have shown evidence that existing cancer drugs could have increased efficacy and reduced side effects when attached to the Polycefin  platform. Polycefin’s have the ability to harbor various drugs at the same time making it a master delivery vehicle that can be customized for a particular tumor and potentially for an individual patient.  Additionally, in vivo testing has shown efficacy against more than one type of cancer (breast and  brain) suggesting that Polycefin may have application to a wide range of cancer types, therapeutics and diagnostics.

Patent Rights
Title
Antisense Inhibition of Laminin-8 expression to Inhibit Human Gliomas
U.S. Patent & Trademark Office
Application No.
10/570,747
Filing Date
January 30, 2007
Patent No.
7,547,511
Issue Date
June 16, 2009

U.S. Patent & Trademark Office
Application No.
12/473,992
Filing Date
May 28, 2009

Japanese Patent Office
Application No.
2006-526391
Filing Date
September 13, 2004

Title
Polymalic Acid-Based Multifunctional Drug
Delivery System
U.S. Patent & Trademark Office
Application No.
10/580,999
Filing Date
March 12, 2007

European Patent Office
Application No.
04813049.6
Filing Date
December 3, 2004

Japanese Patent Office
Application No.
2006-542822
Filing Date
December 3, 2004

Title
Poly(Beta Malic Acid) with Pendant Leu-Leu-Leu
Tripeptide for effective Cytoplasmic Drug deliver

U.S. Patent & Trademark Office
Application No.
PCT/US2009/40252
Filing Date
April 10, 2009

Title
Drug delivery of Temozolomide for Systemic based treatment of Cancer
U.S. Patent & Trademark Office
Application No.
61/285,495
Filing Date
December 10, 2009

Field of Use
Field of Use shall mean human therapeutic products, including new pharmaceutical products and/or non-prescriptive products based on, or utilizing the Patent Rights and/or Technical Information developed in the course of the Program.

IPSCIO Record ID: 315667

License Grant
The Swiss Licensee obtained a worldwide, sub-licensable license from the Licensor covering four different compounds, which included Mazindol (the “Licensed Compounds”). Under the Second Amendment it was agreed to include sales realized upon the commercialization of products developed on the basis of the Licensed Compounds during the terms of their respective patents.  The Licensee’s majority shareholders are also majority shareholders in the Licensor and as such are considered to be related parties.
License Property
Licensed Compound, Mazindol, is an active molecule in a proprietary controlled release formulation. The controlled-release formulations are being designed to optimize their pharmacokinetic and pharmacodynamic properties with a rapid onset of action and prolonged controlled therapeutic effect, allowing for a daily oral dose that effectively provides consistent and long acting symptom control and designed to uniquely meet the needs of patients.

Licensor is primarily focusing on the repurposing of safe and (cost-)effective compounds to treat Attention Deficit/HyperActivity Disorder (ADHD), sleep disorders and cognitive impairment.

Field of Use
Licensee will utilize Mazindol, an active substance, to cover a range of areas including the therapeutic use of mazindol for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and combination therapies containing mazindol (add-ons with iron or stimulants) as well as sleep disorders such as narcolepsy or idiopathic hypersomnia.  Attention Deficit Hyperactivity Disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness.

Licensee is an innovative biotechnology company engaged in the discovery and development of life-improving drug therapies to treat rare and complex central nervous system, or CNS, disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder, or ADHD. CNS disorders are a diverse group of conditions that include neurological, psychiatric, and substance use disorders.

IPSCIO Record ID: 330325

License Grant
Licensor granted a worldwide exclusive, sublicensable license to certain Licensor owned provisional patent applications and any patents issuing therefrom, including all continuations, continuations-in-part, divisions, extensions, substitutions, reissues, re-examinations, and any applications and all patents issuing from any applications and patents that claim domestic benefit or foreign priority to the provisional patent applications.

The Agreement also grants a contingent right to License certain other University licensed Patent Rights, to negotiate with Licensor, to obtain a nonexclusive sublicense in the field of cancer and treating cancer, including neuroinflammatory diseases occurring in any patient diagnosed with cancer.

License Property
The licensed patents relate to the use of psilocybin in cancer treatment, and any patents issuing therefrom, including all continuations, continuations-in-part, divisions, extensions, substitutions, reissues, re-examinations, and any applications and all patents issuing from any applications and patents that claim domestic benefit or foreign priority to the provisional patent applications.

Psilocybin is a naturally occurring psychedelic prodrug compound.

U.S. Provisional Patent Application No. 63/060,573, titled “Central Nervous System Delivery of Psilocybin”

U.S. Provisional Patent Application No. 63/060,569, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin”

U.S. Provisional Patent Application No. 63/060,577, titled “Central Nervous System Delivery of Nonsteroidal Anti-Inflammatory Drugs and Psilocybin”

U.S. Provisional Patent Application No. 63/24,827, titled “Use of Psilocybin in Cancer Treatment”

Field of Use
“Field of Use” means treatment of cancer and symptoms caused by cancer, including but not limited to pain, nausea, neuroinflammation, brain and neural dysfunction, depression, seizures, confusion, dizziness, numbness/tingling, dysfunction of the senses and all other symptoms that are caused by cancer of any type. For the sake of clarity, the Field of Use does not include any potential applications of the Licensed Products and Licensed Processes other than those used in treating cancers and the symptoms caused by the cancers.

IPSCIO Record ID: 26619

License Grant
The Licensor hereby grants to the Licensee and its Affiliates a sole and exclusive worldwide sublicense in all fields of use to practice under the Patent Rights and to utilize the Know-how, and to make, have made, use, lease and/or sell the Licensed Products and to practice the Licensed Processes, to the full end of the term for which the Patent Rights are granted, unless sooner terminated as hereinafter provided.
License Property
The Licensor desires to sublicense of such Patent Rights and Know-how in order to commercialize 06-Benzyl guanine (06BG) and related technologies for the treatment of cancer.

O6-Benzylguanine (O6-BG) is a chemosensitizer that is designed to overcome resistance to a significant class of commonly used chemotherapeutic agents known as O6-alkylating agents.  In preclinical animal studies, treatment with O6-BG increased the anti-tumor activity of these agents in brain, colon, and prostate cancers, as well as in melanoma.   A Phase II development program began in 1999.  O6-BG, a series of related compounds and a gene therapy that the Company believes will enhance the effectiveness of a class of currently used chemotherapeutic agents known as O6-alkylating agents.  O6-BG and related compounds are small molecules for intravenous administration in the treatment of cancer.  The Company believes O6-BG to be capable of destroying the resistance of cancer cells to a class of chemotherapeutic agents, O6-alkylating agents.  The Company believes that the effectiveness of alkylating chemotherapeutic agents against various tumors such as brain, prostate, colon cancers, melanoma and lymphoma is limited due to the ability of tumor cells to repair the DNA damage caused by the O6-alkylating agents, because the DNA repair protein, O6-alkylguanine-DNA alkyltransferase (AGT), protects tumor cells by repairing the tumor cell DNA.

The Company believes that O6-BG inactivates the AGT protein in a variety of cancers thereby overcoming resistance to theO6-alkylating agents.

Field of Use
The rights granted apply in all fields of use relating to technologies for the treatment of cancer.

IPSCIO Record ID: 5499

License Grant
Licensor was formed by licensee to aid in acquiring development funds.  License grants an exclusive interim license to manufacture and market RMPs and Cereport for human pharmaceutical use in the United States and Canada. Designation of European rights are not explained.

The transaction assigned rights to a family of molecules designated as Receptor-Mediated Permeabilizers(TM) (RMPs(TM)), including Cereport.

License Property
Cereport improves the passage into the brain of certain pharmaceutical compounds by increasing transiently the permeability of the blood brain barrier.  It is being tested in conjunction with the chemotherapy agent carboplatin for the treatment of brain tumors.  Patent #5,112,596 and 5,268,164.
Field of Use
The rights granted are for human pharmaceutical use.

IPSCIO Record ID: 256273

License Grant
The German Licensor grants the Swiss Licensee a worldwide, exclusive, right and license, or sublicense, with the right to grant sublicenses, under the Licensed Technology to make, have made, use, offer for sale, sell, and import the Product in the Field in the Territory.

This agreement includes a non-exclusive grant by Licensee to Licensor.

License Property
Licensor is developing a pharmaceutical product comprising a human antibody of IgG-1 subtype binding to EpCAM.

The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.

Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.

Field of Use
The Field means the treatment of human diseases, disorders and conditions.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.